Emcure – Indian Oncology Medicines

Emcure

Country: India

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981 by Satish Mehta and headquartered in Pune, Maharashtra. Since July 2024 its shares have been listed on India's NSE and BSE stock exchanges.

Emcure makes oral and injectable medicines as well as biotech products. Its main areas are gynaecology, cardiology, oncology and haematology, and treatments for HIV and other infections. The company has a long record in antiretroviral therapy: in 2006 it signed licensing agreements with Bristol-Myers Squibb for atazanavir and with Gilead for tenofovir.

The Emcure group includes the biotech company Gennova Biopharmaceuticals. In 2022 its mRNA COVID-19 vaccine, GEMCOVAC-19, received emergency use authorisation in India, becoming the first mRNA vaccine developed in the country.

The company's manufacturing sites are in India. According to Emcure, its products reach more than 70 countries; in Europe and Canada it operates through its subsidiaries Tillomed Laboratories (UK) and Marcan Pharmaceuticals.

Unifarm carries Emcure's HIV and oncology medicines: Viropil (tenofovir, lamivudine and dolutegravir), Instgra (dolutegravir), Megval (melphalan) and Ematra (tretinoin).

Official manufacturer website
Emcure

List of medicines by manufacturer Emcure

-7%
Viropil
View
Emcure
50 мг / 300 мг / 300 мг
2906₴ 3129₴
-8%
Megval
View
Emcure
50 mg 1 vial
3900₴ 4247₴
-11%
Instgra
View
Emcure
50 mg 30 tablets
3576₴ 4023₴
-6%
Ematra
View
Emcure
10 mg 100 capsules
4947₴ 5272₴
✅ All products loaded (4)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00